HCPCS Level II
Q5168
Injection, ranibizumab-leyk (nufymco), biosimilar, 0.1 mg
Codes near Q5168
These sit next to Q5168 in the CMS Level II file. All Q codes
- Q5162Injection, denosumab-nxxp (bildyos/bilprevda), biosimilar, 1 mg
- Q5164Injection, ustekinumab-hmny (starjemza), biosimilar, 1 mg
- Q5165Injection, denosumab-mobz (oziltus), biosimilar, 1 mg
- Q5166Injection, denosumab-desu (osvyrti/jubereq), biosimilar, 1 mg
- Q5167Injection, denosumab-qbde (enoby/xtrenbo), biosimilar, 1 mg
- Q5169Injection, pegfilgrastim-unne (armlupeg), biosimilar, 0.5 mg
- Q5170Injection, aflibercept-boav (eydenzelt), biosimilar, 1 mg
- Q5171Injection, denosumab-mobz (boncresa), biosimilar, 1 mg
- Q5172Injection, filgrastim-laha (filkri), biosimilar, 1 microgram
- Q5173Injection, denosumab-adet (ponlimsi), biosimilar, 1 mg
NDC crosswalk
| NDC | Drug | Labeler | Billable units |
|---|---|---|---|
| 70710-2173-01 | Nufymco | Zydus Pharmaceuticals (USA) Inc. | 5 |
Source: CMS ASP NDC-HCPCS crosswalk, effective October 1, 2026 through December 31, 2026.